|
|
|
|
Partners |
Gilbert Gonzales, M.D., brings 30 years of experience as a physician and entrepreneur to the Partnership. His medical career includes academic positions at the University of Cincinnati and Mayo Clinic Scottsdale. In 1998, he joined Memorial Sloan-Kettering Cancer Center as an attending physician and researcher in the Department of Neurology and Division of Pain and Palliative Care. While at Sloan-Kettering, Dr. Gonzales served as a voting member of the FDA's Neurological and Neurosurgical Devices Section from 1996 to 1999 and as a consultant to the FDA Dental Devices Section from 1997 to 2002. In 2000, he co-founded Drug Enhancement Corporation of America, LLC, a device and drug delivery development company.
Dr. Gonzales joined Essex Woodlands in 2001 as an Adjunct Partner. He was involved in the founding or co-founding of several Essex Woodlands companies, including
Richwood (Shire) Pharmaceuticals, Xanodyne Pharmaceutical, Inc. Prism Pharmaceuticals and
Clear Vascular, Inc. and
PediaMed Pharmaceuticals, and founded or
co-founded
Xanodyne Pharmaceutical,
Dr. Gonzales played a key role in the Partnership's
investment in
Acura Pharmaceuticals, Inc. (formerly Halsey Pharmaceuticals) (NASDAQ: ACUR).
He currently serves on the Board of Directors of
Clear Vascular, Inc.
Dr. Gonzales holds a Bachelor of Science and Doctor of Medicine degree from University of Arizona, where he completed his residency in neurology. He also completed a neuro-oncology pain fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Gonzales has written over 60 publications, including a number of patents in the fields of drug delivery platform technologies, drug life cycle management techniques, new devices and device manufacturing processes.
|
| |
|
|
 |
|
|
|
